Highlights

Paul Alewood graduated from the University of NSW before moving to the University of Calgary for his PhD. His early research interest was in classical organic chemistry, but the discovery in the mid 1970s of encephalins – short-chain amino acids produced in the body that have a similar effect to morphine – triggered an interest in protein and peptide chemistry.

He moved to Queensland, attracted by the state’s healthy populations of dangerous marine animals – cone snails, sea snakes and stone fish, to name a few. Such animals offer vast potential in the treatment of chronic pain, as their venom contains thousands of small peptides that target sensory nerve receptors.

He is the author of more than 300 publications and was a prime mover in establishing the Melbourne-based peptide company, Auspep, and Xenome, a spin-off biopharmaceutical company from the University of Queensland. More recently, he was a foundation scientist at Betabiotics, a joint venture company between IMB and CSIRO, and the founder of Elacor, a joint venture between the University of Queensland and the Baker Heart Research Institute, Victoria.

Researcher biography

Professor Alewood is a Group Leader within the Institute for Molecular Bioscience (IMB) at the University of Queensland and former Head of the Division of Chemical and Structural Biology. He was formerly Associate Professor in the Centre for Drug Design and Development (UQ), Assistant Professor of Peptide Chemistry at Bond University and Lecturer at the Victorian College of Pharmacy. He is internationally and nationally recognised for his research in the field of bioactive peptides and synthetic proteins and is the author of over 300 publications in high quality journals – he is widely recognized for his research on peptide synthesis, structure-activity relationships and peptide toxins.

Featured projects Duration
Venom peptides that target chronic pain